S
Sunil Krishnan
Researcher at Mayo Clinic
Publications - 53
Citations - 1341
Sunil Krishnan is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Radiation therapy & Cancer. The author has an hindex of 12, co-authored 53 publications receiving 754 citations. Previous affiliations of Sunil Krishnan include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Radiosurgery for cranial base chordomas and chondrosarcomas.
Sunil Krishnan,Robert L. Foote,Paul D. Brown,Bruce E. Pollock,Michael J. Link,Yolanda I. Garces +5 more
TL;DR: Radiosurgery as an adjunct to surgical resection provides in-field tumor control for some patients, but radiation-related complications are relatively high, especially when radiosurgery is combined with fractionated radiation therapy.
Journal ArticleDOI
Carbon Ion Therapy: A Modern Review of an Emerging Technology
Timothy D. Malouff,Anita Mahajan,Sunil Krishnan,Chris Beltran,Danushka S. Seneviratne,Daniel M. Trifiletti +5 more
TL;DR: A comprehensive review of the studies of carbon ion radiotherapy for almost every type of malignancy, including intracranial malignancies, head and neck malignANCs, primary and metastatic lung cancers, tumors of the gastrointestinal tract, prostate and genitourinary cancers, sarcomas, cutaneous malIGNancies, breast cancer, gynecologic malignations, and pediatric cancers is provided.
Journal ArticleDOI
H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer
Masahisa Ohtsuka,Hui Ling,Cristina Ivan,Martin Pichler,Martin Pichler,Daisuke Matsushita,Matthew Goblirsch,Verena Stiegelbauer,Kunitoshi Shigeyasu,Xinna Zhang,Meng Chen,Fnu Vidhu,Geoffrey Bartholomeusz,Yuji Toiyama,Masato Kusunoki,Yuichiro Doki,Masaki Mori,Shumei Song,Jillian R. Gunther,Sunil Krishnan,Ondrej Slaby,Ajay Goel,Jaffer A. Ajani,Milan Radovich,George A. Calin +24 more
TL;DR: It is identified that H19 expression in primary tumors is an independent prognostic predictor of poor prognosis of CRC patients and further proved its oncogenic role.
Journal ArticleDOI
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
Sunil Krishnan,Paul D. Brown,Karla V. Ballman,John B. Fiveash,Joon H. Uhm,Caterina Giannini,Kurt A. Jaeckle,Francois J. Geoffroy,L. Burt Nabors,Jan C. Buckner +9 more
TL;DR: Toxicity is acceptable at the current doses of erlotinib plus RT in patients with glioblastoma multiforme in a multicenter phase I trial and accrual is in progress.
Journal ArticleDOI
Roadmap for metal nanoparticles in radiation therapy: current status, translational challenges, and future directions.
Jan Schuemann,Alexander F. Bagley,Ross Berbeco,Kyle Bromma,Karl T. Butterworth,H L Byrne,Devika B. Chithrani,Sang Hyun Cho,Jason R. Cook,Vincent Favaudon,Yaser Hadi Gholami,E. Gargioni,James F. Hainfeld,Félicien Hespeels,Anne-Catherine Heuskin,Udoka Ibeh,Zdenka Kuncic,Sijumon Kunjachan,Sandrine Lacombe,Stéphane Lucas,François Lux,Stephen J. McMahon,Dmitry Nevozhay,Wilfred Ngwa,J Donald Payne,Sébastien Penninckx,Erika Porcel,Kevin M. Prise,Hans Rabus,Sharif M Ridwan,Benedikt Rudek,Léon Sanche,Bijay Singh,Henry M. Smilowitz,Konstantin V Sokolov,Srinivas Sridhar,Yaroslav Stanishevskiy,Wonmo Sung,Olivier Tillement,Needa A. Virani,Wassana Yantasee,Sunil Krishnan +41 more
TL;DR: This roadmap outlines the potential roles of metallic nanoparticles in the field of radiation therapy and covers contributions from experts in these topics summarizing their view of the current status and challenges, as well as expected advancements in technology to address these challenges.